Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-29T23:25:48.105Z Has data issue: false hasContentIssue false
  • English
  • Français

PW01-29 - Mood Stabilizers and Atypical Antipsychotics in Long-term Treatment of Bipolar Disorder

Published online by Cambridge University Press:  17 April 2020

R. Paoli ,
M. Buoli ,
D. Primavera ,
M. Benedetti ,
C. Rovera  and
A.C. Altamura
R. Paoli
Affiliation:
U.O. di Psichiatria, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milano
M. Buoli
Affiliation:
U.O. di Psichiatria, Università di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan
D. Primavera
Affiliation:
Dipartimento di Salute Pubblica, Sezione di Psichiatria, Università di Cagliari, Cagliari, Italy
M. Benedetti
Affiliation:
U.O. di Psichiatria, Università di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan
C. Rovera
Affiliation:
U.O. di Psichiatria, Università di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan
A.C. Altamura
Affiliation:
U.O. di Psichiatria, Università di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

Bipolar Disorder treatment includes not only the remission of Major Depressive or Manic/Hypomanic Episodes, but also the prevention of recurrences. Purpose of this trial is to evaluate the effectiveness of Mood Stabilizers and Atypical Antipsychotics in preventing recurrences.

Methods

67 patients with a diagnosis of Bipolar Disorder type 1 and 2 were followed retrospectively for a period of 48 months. Clinical and demographic information were collected by clinical charts and interviews with patients. A survival analysis was performed considering death events change of treatment, a Major Depressive or Hypomanic/Manic Episode or a hospitalization.

Results

Patients treated with Lithium survived longer than patients treated with Valproate (Log Rank: χ2=3.86, p=0.05) which resulted to be superior in terms of recurrence prevention compared to Atypical Antipsychotics in monotherapy (Olanzapine, Quetiapine or Risperidone) (Log Rank: χ2=4.54, p=0.03). Lithium association with an Atypical Antipsychotic resulted more efficacious in terms of recurrence prevention compared to Lithium (Log Rank: χ2=7.01, p=0.008) or Atypical Antipsychotics in monotherapy (Log Rank: χ2=8.61, p=0.003).

Conclusions

These preliminary data would indicate that Lithium association with an Atypical Antipsychotic would be more effective in preventing Major Depressive or Hypomanic/Manic recurrences in bipolar patients.

Type
Affective disorders / Unipolar depression / Bipolar disorder
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E1431
Copyright
Copyright © European Psychiatric Association 2010

References

Altamura, A.C. Mundo, E. Dell’Osso, B. Tacchini, G. Buoli, M. Calabrese, J.R. Quetiapine And Classical Mood Stabilizers In The Long-term Treatment Of Bipolar Disorder: a 4-year Follow-up Naturalistic. J Affect Disord. 2008 Sep; 110(1–2): 135–141CrossRefGoogle ScholarPubMed
Fountoulakis, K.N. Vieta, E. Treatment Of Bipolar Disorder: a Systematic Review Of Available Data And Clinical Perspectives. Int J Neuropsychopharmacol 2008; 11(7): 999–1029Google Scholar
Submit a response

Comments

No Comments have been published for this article.